A vascularized tumoroid model for human glioblastoma angiogenesis

Agavi Stavropoulou Tatla1, Alexander W. Justin1, Colin Watts2,3 & Athina E. Markaki1,2

Glioblastoma (GBM) angiogenesis is critical for tumor growth and recurrence, making it a compelling therapeutic target. Here, a disease-relevant, vascularized tumoroid in vitro model with stem-like features and stromal surrounds is reported. The model is used to recapitulate how individual components of the GBM’s complex brain microenvironment such as hypoxia, vasculature-related stromal cells and growth factors support GBM angiogenesis. It is scalable, tractable, cost-effective and can be used with biologically-derived or biomimetic matrices. Patient-derived primary GBM cells are found to closely participate in blood vessel formation in contrast to a GBM cell line containing differentiated cells. Exogenous growth factors amplify this effect under normoxia but not at hypoxia suggesting that a significant amount of growth factors is already being produced under hypoxic conditions. Under hypoxia, primary GBM cells strongly co-localize with umbilical vein endothelial cells to form sprouting vascular networks, which has been reported to occur in vivo. These findings demonstrate that our 3D tumoroid in vitro model exhibits biomimetic attributes that may permit its use as a preclinical model in studying microenvironment cues of tumor angiogenesis.
Here, we introduce a 3D vascularized tumoroid in vitro model using patient-derived primary GBM cells. This model is used to recapitulate how individual components of the GBM’s complex brain microenvironment, such as low oxygen tension (e.g. 1% O₂), vasculature-related stromal cells (e.g. human umbilical vein endothelial cells (HUVEC), human dermal fibroblasts (HDF) and growth factors (e.g. VEGF, bFGF), support the GBM angiogenesis.

**Results and discussion**

The vascularized tumoroid model is based on spheroids, in which HUVEC and patient-derived primary GBM are in direct contact with each other, supported by HDF embedded in a fibrin gel (Fig. 1A). The NCH82 GBM cell line is also used. Variants of the model include GBM-only or HUVEC-only spheroids surrounded by HDF, GBM or no cells in the fibrin gel. It should be noted that direct comparison between the two cell lines is not possible because different types of culture medium were used.
Sprouting of HUVEC spheroids. The first challenge towards the development of the vascularized tumoroid model is to provide a suitable environment for the HUVEC spheroids to form capillary sprouts. Angiogenesis is a complex process involving dynamic interactions between the endothelial and stromal cells, the production of angiogenic signalling factors, and is affected by changes in the surrounding ECM (e.g. hypoxic conditions). Fibrin was chosen as the supporting matrix for our experiments because it can be derived directly from the patients’ blood. Variation in the ECM composition is a hallmark of tumor stroma, with increased fibrin deposition associated with tumor angiogenesis. Pro-angiogenic factors, such as VEGF and bFGF, have a high affinity for fibrin through the heparin binding domain. Fibrin also triggers the production of other basement membrane proteins that are strongly linked to angiogenesis such as laminin and collagen IV.

In the absence of a supporting cell type, endothelial cells cultured in spheroids within a fibrin gel undergo a migratory response instead of forming vasculature (Figure S1). In angiogenesis models, a range of supporting cells can be used including human dermal fibroblasts, mesenchymal stromal cells and pericytes. In this study, we used the well-known method of culturing endothelial cells with human dermal fibroblasts, as they undertake significant collagen deposition and produce pro-angiogenic growth factors enabling capillary formation. To this end, HUVEC spheroids are cultured with HDF single cells (at 10^6 cells/mL) within a 7.5 mg/mL fibrin gel to form angiogenic sprouts. Experiments are performed under normoxia (20% O_2) or hypoxia (1% O_2), with or without additional pro-angiogenic growth factors (200 ng/mL VEGF and bFGF). Figure 1B(i) shows a typical HUVEC spheroid at day 3 after seeding (additional timepoints are shown in Figure S2). In all cases the HUVEC display an angiogenic-like response, sprouting radially outwards forming capillaries. The addition of exogenous growth factors, as well as normoxia, induce a stronger angiogenic response compared to hypoxia. Figure 1C(i) shows the increase in vessel area and total vessel length of the produced sprouts at day 3.

Invasion of GBM spheroids. Before incorporating the tumor cells into the sprouting spheroids, the invasion capability of GBM-only spheroids embedded in a fibrin gel was examined for primary and NCH82 GBM cells under hypoxic and normoxic conditions. Figure 1B(ii) shows fluorescence images of the GBM spheroids at day 3. The corresponding total spheroid areas are shown in Fig. 1C(ii). It can be seen that hypoxia significantly increases GBM spheroid area in both primary and NCH82 cells which has been previously reported. This effect appears to be stronger for primary cells compared to NCH82 cells.

Vascularized tumoroid model. The vascularized tumoroid model was created by applying vascularization techniques to tumor spheroids which were presented in the previous section. This model comprises of 1000-cell spheroids, consisting of GBM and HDF cells at a ratio of 3:1, in a 7.5 mg/mL fibrin gel containing 10^6 HDF cells/mL. Both primary and NCH82 GBM cells were used. The primary GBM cells were cultured in serum-free medium that preserves the subpopulation of glioblastoma stem-like cells as demonstrated in previous work using the same cells, whereas the NCH82 GBM cell line was not, resulting in differentiated cells. Culturing GBM cells under serum-free conditions with hEGF and hbFGF has been reported to tentatively preserve the characteristics of the primary brain tumors.

Figure 1B(iii) shows fluorescence images of the GBM : HUVEC spheroids embedded in a 7.5 mg/mL fibrin gel containing HDF single cells, at day 3 under hypoxic and normoxic conditions. This tri-culture method was found to trigger robust HUVEC angiogenesis creating lumens capillaries that sprout radially outwards into the surrounding fibrin gel. As in the case of HUVEC-only spheroids, angiogenic sprouting is higher at 20% O_2 compared to 1% O_2. Moreover, the GBM cells behave differently depending on whether they are primary or not. NCH82 GBM cells invade into the gel without interacting strongly with the endothelial cells (this is more evident at longer timepoints as shown in Figure S3). On the other hand, primary GBM cells integrate more into the vasculature behaving similarly to the HUVEC. This phenomenon will be explored further in the following sections.

GBM promotes angiogenesis. In order to investigate the effect of glioblastoma cells on the sprouting of endothelial cells, the full tumoroid model (GBM : HUVEC spheroid surrounded by HDF single cells) or the exact model but without the GBM cells (HUVEC spheroid with HDF) were compared. Figure 2A depicts the angiogenic sprouting of HUVEC spheroids under various co-culture conditions at 1% and 20% O_2. For each condition, the explant area, the average vessel length and the junction density are presented in Fig. 2B. The results show that in the presence of primary glioblastoma cells, endothelial cells produce vasculature of higher explant area but lower interconnectivity. In addition, an increase in the vessel length was observed under hypoxic conditions only (Fig. 2B). From the above, we hypothesize an invasive mode of angiogenesis for primary GBM cells. This suggests that the cells are producing tumor specific growth factors. The NCH82 GBM cell line interacts differently with the endothelial cells inducing sprouting within a smaller explant area while the average vessel length remains unaffected. As with the primary GBM, capillaries of lower interconnectivity are produced (Fig. 2B).

These results suggest a difference in angiogenic capabilities between primary and NCH82 GBM cells. Patient-derived primary GBM cells have been cultured under conditions that retain their stem-like potential whereas in the serum-grown NCH82 cell line the cells are differentiated. This is consistent with in vivo observations as tumors that have a high stem cell number are highly angiogenic. Furthermore, the lower vascular interconnectivity observed in the presence of GBM cells is an important biomimetic feature as it is consistent with the high amount of dead ends present in the GBM vasculature compared to normal vasculature.

GBM as supporting cells. In a related experiment we tested the hypothesis that primary GBM cells can act as a supporting cell type for vessel formation, role taken up by the fibroblasts in the previous experiment. For this experiment, a 1000-cell GBM spheroid was cultured in a 7.5 mg/mL fibrin gel containing 10^6 cells/mL pri-
mary or NCH82 GBM single cells. The angiogenic sprouting of HUVEC under 1% and 20% O₂, with or without additional growth factors, is illustrated in Fig. 3A for day 3. The number of HUVEC sprouts is shown in Fig. 3B. When primary GBM is used as a supporting cell, endothelial sprouting is more pronounced in hypoxia compared to normoxia (Fig. 3B). The opposite result is observed for HDF supporting cells (Fig. 2A), demonstrating the supporting role primary, serum-free cultured GBM cells have especially under hypoxia even without direct intracellular contact. GBM cells are known to secrete pro-angiogenic factors under hypoxia, such as VEGF and bFGF.34,35

Furthermore, the addition of exogenous growth factors enhances this effect for cells cultured at normoxia but not at hypoxia suggesting that under hypoxia the GBM cells are already producing a significant amount of growth factors (Fig. 3B). In the absence of GBM cells and growth factors, HUVEC undergo a migratory response (Figure S1) which suggests that GBM cells are indeed producing pro-angiogenic factors and these factors recruit cells that may contribute to vessel formation. Performing the same experiment using the NCH82 GBM cells,
GBM angiogenic behavior. Time-lapse images of the GBM vascularized tumoroid model depict the evolution of GBM: HUVEC spheroids with HDF single cells at 1% O₂ over 32 h starting at day 1 after seeding. In a feature unique to primary GBM vascularized tumoroids, tumor cells grow together with the endothelial cells forming sprouting networks. Moreover, as time-lapse imaging shows, some of the formed sprouts are composed of primary GBM cells (Fig. 4A). However, in NCH82 vascularised tumoroids, GBM cells break away from the primary mass and invade separately into the surrounding matrix (Fig. 4B).

The co-localization between the tumor and the endothelial cells is quantified using the Pearson's correlation coefficient (Fig. 4C). The coefficient is steadily high (~0.75 for primary GBM cells but it decreases from ~0.6 to ~0.2 for NCH82 GBM cells over 32 h.

CD31 immunohistochemical staining of primary GBM: HUVEC vascularised tumoroids (Fig. 4D) showed angiogenic sprouting, with cells other than HUVEC expressing CD31, suggesting that the primary GBM cells may have transdifferentiated into endothelial cells (Fig. 4D, arrow in the magnified views of the selected area (yellow box)). This effect was found to be more prominent under hypoxia which is consistent with what has been observed in vivo.66,37

Conclusion
A human, disease-relevant, in vitro vascularized tumoroid model has been developed to investigate microenvironment cues of glioblastoma (GBM) angiogenesis. The model comprises of GBM and endothelial cell (HUVEC) spheroids in a fibrin gel containing human dermal fibroblasts. It is easily scalable, tractable, cost-effective, patient-specific, can employ naturally-derived and synthetic matrices, and is amenable to imaging and detailed analysis such as spheroid growth tracking. Although the model lacks perfusable vasculature and has no pre-existing capillary bed or blood brain barrier, it is complex enough to recapitulate features of GBM angiogenesis, which have previously been observed in vivo. Patient-derived primary GBM cells were found to support angiogenic sprouting when cultured under conditions that preserve their stem-like potential, in contrast to a GBM cell line containing differentiated cells. Angiogenic sprouting was observed even in the absence of supportive fibroblasts. In the presence of exogenous growth factors, sprouting was enhanced under normoxia but not at hypoxia suggesting that hypoxic GBM cells are already producing a significant amount of growth factors. Primary GBM cells co-cultured with HUVEC in spheroids, produced vasculature of higher explant area and lower connectivity in comparison to HUVEC-only spheroids. Under hypoxia, primary GBM cells co-localize with HUVEC to form sprouting vascular networks. These findings demonstrate that our 3D tumoroid in vitro model exhibits biomimetic attributes. It therefore holds potential as a simple reductionist model for the development of anti-angiogenic treatments to GBM especially in view of the need to assess the preliminary effectiveness of new treatments before moving to more complex and lengthy efficacy in vivo models.

Methods
Cell culture. Primary GBM cells from fresh surgical samples (Addenbrooke's Hospital, UK) were derived using the Cambridge Protocol36. Tissue collection protocols complied with the UK Human Tissue Act 2004 (HTA license ref. 12315) and have been approved by the local regional ethics committee (LREC ref. 04/Q0108/60). Cells were cultured in serum-free medium (SFM) based on phenol red-free Neurobasal A medium (Invitrogen, UK) supplemented with 2 mM L-glutamine and 1% Antibiotic - Antimycotic solution. HDF (Public Health England) were cultured in DMEM - high glucose Dulbecco's Modified Eagle's Medium (DMEM - high glucose, Life Tech, UK), containing 10% fetal bovine serum (FBS, Life Tech, UK) and 1% antibiotic antimycotic solution (Sigma-Aldrich, UK). Primary and NCH82 GBM cells were passaged at 80% confluency with accutase (Sigma-Aldrich, UK).

GBM cell line NCH82, a gift from Prof Conceição Pedroso de Lima (University of Coimbra, Portugal), was transduced with GFP through lentiviral infection. The NCH82 cell line was cultured in serum-containing, high glucose Dulbecco's Modified Eagle's Medium (DMEM - high glucose, Life Tech, UK), containing 10% fetal bovine serum (FBS, Life Tech, UK) and 1% antibo tic antimycotic solution (Sigma-Aldrich, UK). Primary and NCH82 GBM cells were passaged at 80% confluency with accutase (Sigma-Aldrich, UK).

Red fluorescent protein expressing HUVEC (2B Scientific, UK) were cultured in Endothelial Growth Medium 2 (EGM2, Promocell, Germany) and 1% antibiotic antimycotic solution. HDF (Public Health England) were cultured in high glucose DMEM containing 10% FBS (Life Technologies, UK) and 1% antibiotic antimycotic solution. HUVEC and HDF were passaged at 80% confluency with TrypLE Express (Life Technologies, UK). All cells were incubated at 37 °C in 5% CO₂ and 95% relative humidity.

Multi-cellular spheroid formation. Co-culture spheroids were prepared using the hanging drop method. A stock solution of methylcellulose was prepared by dissolving 1.2 g methylcellulose powder (Sigma-Aldrich, UK) in 100 mL of DMEM. GBM and/or HUVEC cells were detached and suspended in 1:1 EGM to SFM medium containing 20% methylcellulose (v/v), 20 μL cell suspension drops each containing 1000 cells were pipetted onto a non-adherent petri dish (Greiner, UK). Co-culture spheroids were composed of HUVEC to GBM at a 3:1 ratio. HUVEC-only and GBM-only spheroids were also generated. The dish was turned upside down and incubated at 37 °C. The spheroids were harvested after 16 h.

Gel construct preparation. For each fibrin construct, approximately 3 spheroids were embedded in 25 μL of fibrin gel. Fibrin gels contained HDF or GBM at 10⁶ cells/mL or no cells. To prepare the fibrin gel, fibrinogen was dissolved in 1:1 EGM2 to SFM medium, with or without additional pro-angiogenic growth factors (200 ng/
mL VEGF and bFGF), to a final concentration of 7.5 mg/mL and was mixed with 1 µL of 50 U/mL thrombin. The solution was pipetted into a 48-well plate, turned upside down, left at room temperature undisturbed for 10 min and then moved to a 37 °C incubator for 20 min to completely polymerise. 1:1 EGM to SFM medium was
then added. Fibrin constructs were maintained at either 20% O$_2$ (normoxia) or 1% O$_2$ (hypoxia). Medium was changed every 2 days.

**Fluorescent labelling.** Primary GBM cells were labelled using Qtracker 525 (ThermoFisher Scientific, UK). Cells were subcultured at a density of $2 \times 10^3$ cells per well of a 48-well plate and incubated overnight. Then 200 µL of 15 nM Qtracker diluted in SFM was added per well. Cells were then incubated for 6 h before washing them twice with SFM.

Tumoroids were immunofluorescently stained with CD31 antibody. Gel constructs were fixed using 4% paraformaldehyde (PEA, Sigma-Aldrich, UK) for 1 h followed by washes with phosphate-buffered saline (PBS, Sigma-Aldrich, UK). The constructs were subsequently permeabilised with 0.25% Triton X-100 (Sigma, Sigma-Aldrich, UK) and blocked with 1% bovine serum albumin (BSA, Sigma-Aldrich, UK). Cells were incubated overnight with CD31 antibody (Abcam, UK) diluted at 1:100 followed by 2 h of incubation with 1:500 AlexaFluor 568 goat anti-mouse IgG (abcam, UK) diluted at 1:500. Washes with PBS followed both incubation periods.

**Visualization and quantification of sprouting angiogenesis.** Images of sprouting tumoroids were taken using epifluorescence microscopy (Zeiss Axio Observer Z1 inverted microscope with an ORCA-Flash4.0 camera). The microscope was equipped with an incubator regulating CO$_2$ (5%), O$_2$ (20% or 1%), temperature (37°C) and humidity (95%) (Okolab, Italy). Time-lapse images were acquired every 20 min. The images were the result of the deconvolution of an image z-stack using ZEN 3.0 software.

The area of the vessel networks that extended beyond the surface of the initial spheroid boundary was selected using ImageJ. This area was then analysed using AngioTool. The software provided automatic measurements of: (i) the total vessel area, (ii) the total vessel length, (iii) the explant area (area of convex hull containing all the vessels), (iv) the average vessel length and (v) the junction density (total number of vessel junctions normalised by the area). A vessel was defined as the segment between two junction points or a junction point and an end point. The total spheroid area (area of spheroid including any sprouting) was quantified using ImageJ.

GBM co-localization along blood vessels was quantified by the Pearson’s correlation coefficient in Coloc 2 (Image) plugin).

**Statistical analysis.** Data comparisons between two sets of data were performed in GraphPad Prism 8.4.3 software. Data are displayed as mean ± standard deviation. Three spheroids were analysed out of each one of three independent experiments. The explant area of each spheroid ranged between 0.1 and 1.3 mm$^2$. Two sets of data were compared using the Students t-test. The threshold for statistical significance was set at a value of *p* < 0.05, **p** < 0.01; ***p*** < 0.001.

**Accession codes.** The datasets generated and analysed during the current study are available to download from Mendeley Data, V1, https://doi.org/10.17632/kc64v677tb.1.

Received: 10 May 2021; Accepted: 9 September 2021
Published online: 01 October 2021

**References**

1. Van Schaijik, B. et al. Circulating tumor stem cells and glioblastoma: A review. J. Clin. Neurosci. 61, 5–9 (2019).
2. Rezk, R. et al. Spatial heterogeneity of cell-matrix adhesive forces predicts human glioblastoma migration. Neuro-Oncol. Adv. 2, vdaa081 (2020).
3. Cheng, L. et al. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 153, 139–152 (2013).
4. Hambardzumyan, D. & Bergers, G. Glioblastoma: Defining tumor niches. Trends Cancer 1, 252–265 (2015).
5. Novak, U. & Kaye, A. H. Extracellular matrix and the brain: Components and function. J. Clin. Neurosci. 7, 280–290 (2000).
6. Serres, E. et al. Fibronectin expression in glioblastomas promotes cell cohesion, collective invasion of basement membrane in vitro and orthotopic tumor growth in mice. Oncogene 33, 3451–3462 (2014).
7. Rascher, G. et al. Extracellular matrix and the blood-brain barrier in glioblastoma multiforme: Spatial segregation of tenascin and agrin. Acta Neuropathol. 104, 85–91 (2002).
8. Heffernan, J. M., Överstreet, D. J., Le, L. D., Vernon, B. L. & Satriani, R. W. Bioengineered scaffolds for 3d analysis of glioblastoma proliferation and invasion. Ann. Biomed. Eng. 43, 1965–1977 (2015).
9. Stewart, D. C., Rubiano, A., Dyson, K. & Simmons, C. S. Mechanical characterization of human brain tumors from patients and comparison to potential surgical phantoms. PloS ONE 12, e0177561 (2017).
10. Wolf, K. J., Chen, I., Coombes, J. D., Aghi, M. K. & Kumar, S. Dissociating and rebuilding the glioblastoma microenvironment with engineered materials. Nat. Rev. Mater. 4, 651–668 (2019).
11. Ling, C. et al. Endothelial cell hypertrophy and microvascular proliferation in meningiomas are correlated with higher histological grade and shorter progression-free survival. J. Neuropathol. Exp. Neurol. 2, 95 (2016).
12. Norden, A. D., Drappatz, J. & Wen, P. Y. Antiangiogenic therapies for high-grade glioma. Nat. Rev. Neurol. 5, 610 (2009).
13. Colwell, N. et al. Hypoxia in the glioblastoma microenvironment: Shaping the phenotype of cancer stem-like cells. Neuro Oncol. 19, 887–896 (2017).
14. Gabriely, G., Wheeler, M. A., Takenaka, M. C. & Quintana, F. J. Role of ahr and hif-1a in glioblastoma metabolism. Trends Endocrinol. Metab. 28, 428–436 (2017).
15. Bao, S. et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Can. Res. 66, 7843–7848 (2006).
16. Foksins, C. et al. Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Can. Res. 69, 7243–7251 (2009).
Author contributions
A.S.T., A.W.J. and A.E.M. designed research; A.S.T. performed research, analysed data and prepared figures; C.W. contributed primary cell lines; A.S.T. wrote the main manuscript text; A.W.J. and A.E.M. contributed to writing the manuscript. All authors reviewed the manuscript.

Acknowledgements
This research was supported by an Engineering for Clinical Practice grant (to AEM and CW) and an EPSRC IAA Fellowship Fund (EP/R511675/1 to AEM). Financial support for AST and AWJ has been provided via an WD Armstrong studentship and EPSRC (EP/R511675/1), respectively. The authors would like to thank Dr Rasha Rezk (University of Cambridge, UK) and Prof Conceição Pedroso de Lima (University of Coimbra, Portugal) for providing the patient-derived primary GBM cells and the NCH82 GBM cell line, respectively. We also thank Dr John Ong (University of Cambridge, UK) for helpful discussions on antibodies.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-98911-y.

Correspondence and requests for materials should be addressed to A.S.T. or A.E.M.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
